September 12, 2016
Alizé Pharma III presents preclinical results from its I-HBD1 program at the Annual Meeting of the American Society for Bone and Mineral Research


July 18, 2016
Alizé Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences


May 11, 2016
Alizé Pharma II, a company of the Alizé Pharma Group, acquired by Jazz Pharmaceuticals


April 26, 2016
Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome


October 29, 2015
Alizé Pharma reports positive safety and efficacy results from a Phase Ib trial of AZP-531 in type 2 diabetes and provides an update on its overall clinical program


May 26, 2015
Alizé Pharma presents clinical results from the AZP-531 program at the American Diabetes Association 75th Scientific Sessions


April 16, 2015
Alizé Pharma wins Biovision Investor Conference Award


March 17, 2015
Alizé Pharma III raises €1.8 million ($1.94 million) in first financing round


March 2, 2015
Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome


December 10, 2014
Alizé Pharma announces positive results for AZP-531, its unacylated ghrelin analog, from two Phase I clinical trials in healthy volunteers and obese subjects


December 3, 2014
Alizé Pharma acquires exclusive worldwide rights on a new peptide to tackle bone diseases


September 10, 2014
Alizé Pharma raises EUR 5 million (USD 6.6 million) from Bpifrance/InnoBio and its existing shareholders


July 15, 2013
Alizé Pharma launches the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes


January 3, 2013
Alizé Pharma launches the PREMAG research program


June 4, 2012
Alizé Pharma closes 3.3 million euro funding round


February 2, 2012
Alizé Pharma licenses its ASPAREC® therapy for Treatment of Acute Lymphoblastic Leukemia (ALL) to EUSA Pharma


June 25, 2010
Alizé Pharma signs research collaboration and license option agreement with Lilly


December 3, 2009
Alizé Pharma reveals promising data on Asparec® program for second-line ALL therapy


September 1, 2009
Alizé Pharma closes EUR 3 million (USD 4.2M) financing round


May 6, 2008
Alizé Pharma broadens its porofolio with the acquisition of a recombinant L-asparaginase program from EUSA Pharma


September 18, 2007
Alizé Pharma completes a financing round and strengthens its board